Medical electronics company ZOLL Medical Corporation has acquired Israel-based Kyma Medical Technologies, Ltd., which develops technologies to measure early signs of congestive heart failure.
Kyma's µ-Cor System uses radio frequency-based technology to monitor the level of fluid in the lungs. It also collects data on heart rate, respiration rate, activity, and posture, all of which are analyzed using proprietary algorithms to determine patient-specific vital signs trends. Once a potential deterioration in the patient’s condition is identified, a notification is sent to the patient’s medical team.
“The acquisition of Kyma Medical will allow ZOLL to broaden its product offerings with additional technologies designed to improve outcomes for heart failure patients with fluid management problems, with the goal of reducing hospitalizations," said Jason T. Whiting, President of ZOLL LifeVest. “With the acquisition, Kyma’s technology will be able to better reach global markets through ZOLL’s existing network. Additionally, we expect to leverage Kyma’s strong R&D capabilities as well as the broader research talent available in Israel.”
“ZOLL provides Kyma with an increased infrastructure of clinical and commercial resources that will enable our technology to reach a greater number of clinicians and patients,” said Murali Srivathsa, Kyma President & CEO. “This agreement gives Kyma the opportunity to become part of a company with a long and sustained commitment to improving patient outcomes.”
“We are very proud of Kyma’s technological achievements and are extremely pleased that ZOLL has decided to acquire Kyma,” said Guy Katsav, Chairman of Kyma. “The strategic and cultural fit between ZOLL and Kyma represents the best opportunity to bring Kyma’s innovative technologies to patients worldwide.”
In January 2015, Kyma announced that it had received CE Mark approval for the µ Cor System for monitoring thoracic fluid content, ECG, heart rate, respiration rate, activity, and posture.
ZOLL said it plans to maintain Kyma’s facilities and workforce in Israel and California as a part of ZOLL’s LifeVest division.